The risk for disease progression or death was reduced by 51% with subcutaneous Darzalex Faspro in certain patients with ...

Johnson & Johnson has announced data highlighting that Darzalex Faspro (daratumumab and hyaluronidase-fihj)-based regimens improve overall and sustained minimal residual disease (MRD) negativity rates ...

Johnson & Johnson (JNJ) announced data highlighting that DARZALEX FASPRO (daratumumab and hyaluronidase-fihj)-based regimens improve ...

Treatment with subcutaneous daratumumab significantly improved progression-free survival in patients with intermediate- or high-risk smoldering multiple myeloma.

Darzalex Faspro looks set to transform the prospects for the 30,000 to 45,000 people in the US and Europe AL amyloidosis patients. It has already been submitted for approval in the EU.

Darzalex Faspro's FDA application targets high-risk smoldering multiple myeloma, a precursor to active multiple myeloma with no current approved treatments. The phase 3 AQUILA study supports the ...

Johnson & Johnson (JNJ) announced new frontline data featuring TECVAYLI (teclistamab-cqyv) from two investigational studies in ...

Saad Z. Usmani, MD, MBA, FACP, FASCO, discusses the CEPHEUS trial results and impact on frontline treatment in ...

Darzalex comes in two forms: Darzalex and Darzalex Faspro. This article focuses mainly on the side effects of Darzalex. To read about the differences in side effects between the two forms of ...

It’s meant to be a long-term treatment. Darzalex and Darzalex Faspro are both approved to treat multiple myeloma in certain situations. Darzalex Faspro is also approved to treat light-chain ...

(RTTNews) - Johnson & Johnson (JNJ), Friday announced the submission of regulatory applications for Darzalex Faspro to the U.S. Food and Drug Administration, and Darzalex to the European Medicines ...

Moreover, on November 8, 2024, the company announced the filing of regulatory applications to the FDA and EMA seeking approval of Darzalex Faspro for the treatment of high-risk smoldering MM.